Global pharmaceutical supply chains are scaling continuous synthesis infrastructure to address sustained global shortages of GLP-1 receptor agonists. Traditional batch manufacturing methodologies are being replaced by automated continuous-flow reactors to boost throughput.
Regulatory Acceleration
Health authorities have implemented expedited review pathways for facility retrofits that incorporate real-time analytical technology. This shift reduces batch testing cycles from weeks to hours, accelerating time-to-market for critical therapeutics.